Influence of concurrent medications on outcomes of men with prostate cancer included in the TAX 327 study

Authors

  • Saroj Niraula Division of Medical Oncology, Princess Margaret Hospital/University of Toronto, Toronto, ON
  • Greg Pond Department of Oncology, McMaster University, Hamilton, ON
  • Ronald de Wit Department of Medical Oncology, Rotterdam Cancer Institute/Erasmus University Medical Center, Netherlands
  • Mario Eisenberger Department of Oncology and the Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medical Institutions, Baltimore, MD
  • Ian F. Tannock Division of Medical Oncology, Princess Margaret Hospital/University of Toronto, Toronto, ON
  • Anthony M. Joshua Division of Medical Oncology, Princess Margaret Hospital/University of Toronto, Toronto, ON

DOI:

https://doi.org/10.5489/cuaj.267

Abstract

Objectives: The TAX 327 trial was pivotal in establishing docetaxel in castration refractory metastatic prostate cancer. Various commonly prescribed and over-the-counter co-administered medications are thought to exhibit anti-neoplastic properties and/or could potentially have pharmacokinectic interactions with docetaxel lessening the effectiveness of chemotherapy.

Methods: To examine the effect of on prostate cancer outcomes within this trial, we examined overall survival, prostate-specific antigen (PSA) response, percent PSA reduction, pain response and QOL responses for 14 families of medications including metformin, digoxin, verapamil, proton pump inhibitors, nitrates, statins, cox-2 inhibitors, warfarin, heparins, ascorbic acid, selenium, tocopherol,antidepressants and erythropoietin.

Results: Our findings did not reveal any medication that had asignificant additive or synergistic effect with docetaxel. We did note, however, that patients on digoxin or verapamil had pooreroverall survival, possibly due to a trend of fewer cycles of administered chemotherapy being administered to the verapamil group,consistent with a pharmacokinectic interaction.

Conclusions: These data are only hypothesis-generating given the statistical limitations, but may form a basis for similar future analysis in other malignancies. The data suggest the need to be aware of pharmacokinectic interactions with medications that may interactwith docetaxel.

Downloads

Download data is not yet available.

Downloads

Published

2013-02-20

How to Cite

Niraula, S., Pond, G., de Wit, R., Eisenberger, M., Tannock, I. F., & Joshua, A. M. (2013). Influence of concurrent medications on outcomes of men with prostate cancer included in the TAX 327 study. Canadian Urological Association Journal, 7(1-2), E74–81. https://doi.org/10.5489/cuaj.267

Issue

Vol. 7 No. 1-2 (2013): CUAJ February

Section

Original Research

License

You, the Author(s), assign your copyright in and to the Article to the Canadian Urological Association. This means that you may not, without the prior written permission of the CUA:

  • Post the Article on any Web site
  • Translate or authorize a translation of the Article
  • Copy or otherwise reproduce the Article, in any format, beyond what is permitted under Canadian copyright law, or authorize others to do so
  • Copy or otherwise reproduce portions of the Article, including tables and figures, beyond what is permitted under Canadian copyright law, or authorize others to do so.

The CUA encourages use for non-commercial educational purposes and will not unreasonably deny any such permission request.

You retain your moral rights in and to the Article. This means that the CUA may not assert its copyright in such a way that would negatively reflect on your reputation or your right to be associated with the Article.

The CUA also requires you to warrant the following:

  • That you are the Author(s) and sole owner(s), that the Article is original and unpublished and that you have not previously assigned copyright or granted a licence to any other third party;
  • That all individuals who have made a substantive contribution to the article are acknowledged;
  • That the Article does not infringe any proprietary right of any third party and that you have received the permissions necessary to include the work of others in the Article; and
  • That the Article does not libel or violate the privacy rights of any third party.